Clinical trials: Chronic Nephropathy
End Stage Renal Disease, Coronary Artery Disease
Coronary Artery Disease Screening in Kidney Transplant Candidates
Kidney transplant candidates are at very high risk for coronary artery disease (CAD). The optimal strategy to monitor and maintain the cardiac fitness of patients awaiting kidney transplantation is unknown.
- Trial name
- CADScreening (NCT02082483)
- Testing
- Selective Screening
- Where
- 6 sites in Canada
- Volunteers
- 144 people
- Sponsor
- University of British Columbia
End Stage Renal Disease (ESRD), Maintenance Hemodialysis
Impact of APP-assisted Patient Management on the Quality Control of Blood Purification Therapy
Many maintenance hemodialysis (MHD) patients develop negative outlooks due to their illnesses and complications, making their quality of life and prognosis a clinical concern.
- Trial name
- NCT07291154
- Testing
- APP-based management
- Where
- China
- Volunteers
- 392 people
- Sponsor
- Yunfeng Xia
Hepatitis C, Chronic
HELPS Study - A Study of Peginterferon Alfa-2a (Pegasys) in Patients With Chronic Hepatitis C (CHC) and End-Stage Renal Disease (ESRD)
This study evaluated the safety and efficacy of peginterferon alfa-2a monotherapy in participants with Chronic Hepatitis C (CHC) who have End-Stage Renal Disease (ESRD) and were undergoing hemodialysis.
- Trial name
- NCT02806505
- Testing
- Peginterferon alfa-2a
- Where
- 22 sites in Austria, Brazil and 6 more
- Volunteers
- 81 people
- Sponsor
- Hoffmann-La Roche
Chronic Kidney Diseases, Dialysis-dependent Kidney Failure
Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease
The TRACK trial is an investigator-initiated, multicentre, prospective, randomised, quadruple-blind (participant, healthcare provider, data collector, outcomes assessor), placebo-controlled trial.
- Conditions
- Chronic Kidney Diseases, Dialysis-dependent Kidney Failure, Cardiovascular Disease
- Trial name
- TRACK (NCT03969953)
- Testing
- Rivaroxaban 2.5 Mg Oral Tablet
- Where
- 88 sites in Australia, Belgium and 10 more
- Volunteers
- 1,753 people
- Sponsor
- The George Institute
Restless Legs Syndrome, End Stage Renal Disease
Effectiveness of Ropinirole and Gabapentin for the Treatment of RLS in Patients on Maintenance HD
Restless legs syndrome (RLS) is a neurologic disorder characterized by 1) an urge to move the legs, 2) uncomfortable sensations in the legs, 3) symptoms that are often worse the evening or when at rest , and 4) may be temporarily…
- Trial name
- NCT03708237
- Testing
- Ropinirole, Gabapentin
- Where
- 4 sites in Canada
- Volunteers
- 3 people
- Sponsor
- University of Alberta
Chronic Kidney Disease(CKD)
Functional Capacity in Children with Chronic Kidney Disease
The aim of our study is to assess the functional capacity of children with chronic kidney disease using various tests.
- Trial name
- NCT06683339
- Where
- Turkey (Türkiye)
- Volunteers
- 26 people
- Sponsor
- Hacettepe University
End Stage Renal Disease
A Phase II, Randomized, Cross-Over, Vehicle-Controlled, Double-Blind, Multicenter Study of the Safety, Pharmacodynamics, and Preliminary Efficacy of GHRP-1/AG in Subjects With ESRD on Hemodialysis
Malnutrition and altered protein catabolism are serious problems in renal failure and hemodialysis (HD) patients. The purpose of this study is to characterize the safety of GHRP-1/AG in subjects with ESRD on HD; to characterize…
- Trial name
- NCT00381602
- Testing
- GHRP-1/AG 70 mg depot in ESRD
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- QLT Inc.
Chronic Kidney Disease
Uraemic Toxins in Chronic Kidney Disease Paediatric Patients: Interventional Study
Children with chronic kidney disease (CKD) suffer from one of the most devastating diseases in childhood resulting in a lifelong need for health care, and a 3 times decreased life expectancy.
- Trial name
- UToPaed_3 (NCT02634775)
- Testing
- Change in treatment strategy
- Where
- Belgium
- Volunteers
- 60 people
- Sponsor
- University Hospital, Ghent
Chronic Kidney Disease
Sleep Disturbances as a Risk Factor in Chronic Kidney Disease
This study is designed to determine if either short night time sleep or poor night time sleep could be a risk factor for increasing the rate at which kidney function deteriorates in persons with mild to moderate kidney disease.
- Trial name
- CRIC (NCT00817427)
- Testing
- Controls Short sleep, CKD- sleep extension
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Chicago
End Stage Chronic Renal Failure, Congestive Heart Failure (CHF)
The FILTRATE Trial: High-Rate Ultrafiltration for Intravascular Congestion
The purpose of this study is to evaluate whether a personalized, high-rate fluid removal strategy guided by ultrasound is as safe and effective as the standard fluid removal rate for patients with advanced kidney disease who are…
- Conditions
- End Stage Chronic Renal Failure, Congestive Heart Failure (CHF), Intravascular Congestion, Fluid Overload
- Trial name
- FILTRATE (NCT07705269)
- Testing
- High-rate ultrafiltration, Standard fluid removal
- Where
- Mexico
- Volunteers
- 70 people
- Sponsor
- Universidad Autonoma de Nuevo Leon
Chronic Kidney Diseases, Diabetes Mellitus
Inflammation and Stem Cells in Diabetic and Chronic Kidney Disease
The proposed studies will examine the effect of fisetin on adipose tissue-derived mesenchymal stem/stromal cell function, kidney function, markers of inflammation, and physical function in individuals with advanced chronic kidney…
- Conditions
- Chronic Kidney Diseases, Diabetes Mellitus, Diabetic Nephropathies
- Trial name
- NCT03325322
- Testing
- Fisetin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Sickle Cell Disease, Kidney Diseases, Chronic
The Predictive Capacity of Machine Learning Models for Progressive Kidney Disease in Individuals With Sickle Cell Anemia
This is a multicenter prospective, longitudinal cohort study which will evaluate the predictive capacity of machine learning (ML) models for progression of CKD in eligible patients for a minimum of 12 months and potentially for…
- Trial name
- PREMIER (NCT05214105)
- Testing
- Biospecimen/DNA collection and analysis
- Where
- 3 sites in United States
- Volunteers
- 400 people
- Sponsor
- University of Tennessee
End-stage Renal Disease
Clearum High Flux Hemodialyzer Used in Hemodialysis for Subjects With End-Stage Renal Disease
The study will be a prospective, interventional, non-randomized, single-center study in 20 ESRD patients on hemodialysis. The study will compare performance of the Clearum HS dialyzer to typical values obtained with other…
- Trial name
- NCT04395131
- Testing
- Clearum HF Hemodialyzer
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Mozarc Medical US LLC
Kidney Failure, Chronic
Evaluation of the Integrated Home Dialysis Model
The purpose of this study is to evaluate which home dialysis modality pattern (home hemodialysis [HHD], peritoneal dialysis [PD] or a combination of both, e.g.
- Trial name
- NCT02278159
- Testing
- Peritoneal dialysis, Home hemodialysis
- Volunteers
- 11,600 people
- Sponsor
- Princess Alexandra Hospital, Brisbane, Australia
Chronic Kidney Disease
Study of the Compliance With Phosphorus Restricted Diet and Phosphate Binder Therapy in Hemodialysis Patients
Hyperphosphatemia is a common and severe complication in chronic kidney disease patients treated with hemodialysis. A phosphate restricted diet and oral phosphate binders are the cornerstones in the prevention and treatment of…
- Trial name
- NCT01509027
- Testing
- education by DVD, Standard care, Education by DVD and dietician
- Where
- Belgium
- Volunteers
- 150 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Metastatic Cancer, Congestive Heart Failure
Reducing Disparities in the Quality of Advance Care Planning for Older Adults
This study compares the effectiveness of two different approaches to advance care planning among older African Americans and older Whites living in the community.
- Conditions
- Metastatic Cancer, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, Parkinson Disease
- Trial name
- EQUALACP (NCT03516994)
- Testing
- Respecting Choices First Steps, Five Wishes Form
- Where
- 4 sites in United States
- Volunteers
- 790 people
- Sponsor
- Duke University
Acute Renal Failure, Acute Kidney Tubular Necrosis
Predictive Value of PIIINP and Urinary NGAL in Renal Function Recovery
Acute Renal Failure (ARF) is defined by a severe, and usually reversible, glomerular filtration rate decreasing. Acute Tubular Necrosis (ATN) remain the major cause of ARF involving distress and destruction of tubular cells.
- Conditions
- Acute Renal Failure, Acute Kidney Tubular Necrosis, Chronic Kidney Failure
- Trial name
- PIIINP-NGAL (NCT02889575)
- Where
- France
- Volunteers
- 287 people
- Sponsor
- Nantes University Hospital
Diabetic Kidney Disease, Type 2 Diabetes
Improving Kidney Care in Type 2 Diabetes: A Study of Pharmacist Prescribing Versus Usual Care
Type 2 diabetes is the leading cause of chronic kidney disease, which can result in serious complications such as kidney failure and heart disease.
- Conditions
- Diabetic Kidney Disease, Type 2 Diabetes, Chronic Kidney Disease
- Trial name
- RX4DKD (NCT07169422)
- Testing
- Usual care for diabetic kidney disease management without primary care provider., Pharmacist-led validated diabetic kidney disease decision support algorithm.
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Nova Scotia Health Authority
End Stage Renal Disease, Chronic Kidney Disease
Palm Tocotrienols in Chronic Hemodialysis (USA)
Patients undergoing chronic hemodialysis are at increased risk for cardiovascular disease, attributed in part to increased oxidative stress, inflammation and dyslipidemia.
- Trial name
- PATCH (NCT02358967)
- Testing
- TRF (Tocotrienol-rich-fraction)
- Where
- United States
- Volunteers
- 280 people
- Sponsor
- Wayne State University
Hyperlipidemia, Mixed Dyslipidemia
Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of Evolocumab
The primary objective of this study was to evaluate the pharmacokinetics of evolocumab after a single 140 mg subcutaneous (SC) dose in aduts with normal renal function or severe renal impairment or end-stage renal disease (ESRD)…
- Trial name
- NCT02275156
- Testing
- Evolocumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Amgen